Parinaud J, Fournié A, Grandjean H, Blanc M, Pontonnier G
J Gynecol Obstet Biol Reprod (Paris). 1983;12(4):407-13.
A group of 14 pregnant women with severe Rh-iso-immunization were treated by the administration of oral antigens (stromas). The aim of the treatment was to try to induce a modification of the immune response of these patients in order to minimize the fetal or neonatal consequences of their Rh-iso-immunization. The progress and outcome of the treated pregnancies are compared with those of a group of women presenting an Rh-iso-immunization of comparable severity treated according to standard methods. Stroma therapy is found to be without any danger for the mother or fetus. Even though there are 9 surviving infants in the treatment group and only 5 in the control group, the analysis of the results does not show any statistically significant difference in the two series. The results of this preliminary study would seem to justify the creation of a therapeutic trial.
一组14名患有严重Rh血型免疫的孕妇接受了口服抗原（基质）治疗。治疗的目的是试图诱导这些患者的免疫反应发生改变，以尽量减少其Rh血型免疫对胎儿或新生儿的影响。将接受治疗的妊娠的进展和结果与一组按照标准方法治疗的、具有相当严重程度Rh血型免疫的女性的进展和结果进行比较。发现基质疗法对母亲或胎儿没有任何危险。尽管治疗组有9名存活婴儿，而对照组只有5名，但结果分析显示这两个系列没有任何统计学上的显著差异。这项初步研究的结果似乎为开展一项治疗试验提供了依据。
